Key terms
About KOD
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest KOD news
Apr 04
6:22am ET
Kodiak Sciences price target raised to $5 from $3 at UBS
Apr 01
4:34am ET
Kodiak Sciences price target raised to $3 from $2 at Barclays
Apr 01
3:40am ET
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), Walgreens Boots Alliance (WBA) and Kodiak Sciences (KOD)
Mar 29
9:25pm ET
Barclays Sticks to Their Sell Rating for Kodiak Sciences (KOD)
Mar 28
3:55pm ET
Kodiak Sciences to hold a conference call
Mar 28
12:07pm ET
Kodiak Sciences to hold a conference call
Mar 28
6:41am ET
Kodiak Sciences reports Q4 EPS ($1.13), consensus (77c)
Jan 25
10:44am ET
Capital One says buy these six biotech stocks for 2024
Jan 25
10:44am ET
Capital One says buy these six biotech stocks for 2024
Jan 25
9:03am ET
Capital One reveals top six biotech picks for 2024
No recent press releases are available for KOD
KOD Financials
Key terms
Ad Feedback
KOD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
KOD Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
